Liraglutide Injection (Victoza)

Elliott, William T.; Chan, James
March 2010
Internal Medicine Alert;3/15/2010, Vol. 32 Issue 5, p37
The article offers information on liraglutide, a second human glucagon-like peptide 1 analog/receptor agonist for the treatment of type 2 diabetes mellitus (DM2), with details on indications, dosage, and potential advantages and disadvantages.


Related Articles

  • Treating patients with type 2 diabetes: What is after lifestyle management and metformin? A focus on the glucagon-like peptide-1 receptor agonists.  // Journal of Family Practice;Sep2009 Treating Patients, Vol. 58, pS19 

    The article discusses various reports published within the issue, including the effectiveness of lifestyle management and metformin to treat type 2 diabetes mellitus (T2DM), the efficacy of patient-centered approach for glucagon-like peptide-1 (GLP-1) and the recommendations of the American...

  • GLP-1 RECEPTOR AGONIST THERAPY. Hensler, Paula // GP: General Practitioner;1/21/2013 Diabetes Supplement, p2 

    The article focuses on glucagon-like peptide 1 (GLP-1) receptor agonist therapy and its role in treatment pathway for type 2 diabetes. The effects of GLP-1 receptor agonists include increase in insulin production after meals, satiety and reduced appetite and reduction in glucagon secretion. They...

  • Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Young, Andrew A.; Gedulin, Bronislava R.; Bhavsar, Sunil; Bodkin, Noni; Jodka, Carolyn; Hansen, Barbara; Denaro, Maurizio; Young, A A; Gedulin, B R; Bhavsar, S; Bodkin, N; Jodka, C; Hansen, B; Denaro, M // Diabetes;May99, Vol. 48 Issue 5, p1026 

    Exendin-4 is a 39 amino acid peptide isolated from the salivary secretions of the Gila monster (Heloderma suspectum). It shows 53% sequence similarity to glucagon-like peptide (GLP)-1. Unlike GLP-1, exendin-4 has a prolonged glucose-lowering action in vivo. We compared the potency and duration...

  • Liraglutide leads over the longterm for T2DM in 6 countries.  // PharmacoEconomics & Outcomes News;11/26/2011, Issue 642, p13 

    The article discusses a study which compared the long-term cost effectiveness of liraglutide with exenatide in patients with type 2 diabetes mellitus who failed to respond to metform and/or sulfonylurea.

  • Linagliptin linked to better blood sugar in black patients with type 2 diabetes. Costa, Samantha; Fisher, Stacey L.; Foster, Melissa // Endocrine Today;Jun2012, Vol. 10 Issue 6, p17 

    The article focuses on the effectiveness of linagliptin in improving the blood sugar levels of African American patients with type 2 diabetes, as discussed by researcher James Thrasher at the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific and Clinical Congress...

  • Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. Russell, Sheldon // International Journal of Clinical Pharmacy;Apr2013, Vol. 35 Issue 2, p159 

    Background Clinical trials comparing incretin-based therapies-glucagon-like peptide-1 receptor agonists (exenatide-twice daily and once weekly-and once-daily liraglutide) and dipeptidyl peptidase-4 inhibitors (vildagliptin, sitagliptin, saxagliptin and linagliptin)-with placebo and oral...

  • Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Zander, Mette; Taskiran, Mustafa; Toft-Nielsen, Mai-Britt; Madsbad, Sten; Holst, Jens Juul; Zander, M; Taskiran, M; Toft-Nielsen, M B; Madsbad, S; Holst, J J // Diabetes Care;Apr2001, Vol. 24 Issue 4, p720 

    Objective: The incretin hormone glucagon-like peptide-1 (GLP-1) reduces plasma glucose in type 2 diabetic patients by stimulating insulin secretion and inhibiting glucagon secretion. The biguanide metformin is believed to lower plasma glucose without affecting insulin secretion. We...

  • The central GLP-1: implications for food and drug reward. Skibicka, Karolina P. // Frontiers in Neuroscience;Sep2013, Vol. 7, following p1 

    Glucagon-like-peptide-1 (GLP-1) and its long acting analogues comprise a novel class of type 2 diabetes (T2D) treatment. What makes them unique among other T2D drugs is their concurrent ability to reduce food intake, a great benefit considering the frequent comorbidity of T2D and obesity. The...

  • Comparative safety of GLP-1 agents in T2DM.  // Reactions Weekly;5/1/2013, Issue 1450, p4 

    The article presents the study on the glucagon-like peptide-1 (GLP-1) agents as the treatment of type 2 diabetes mellitus (T2DM) which is associated with greater risks of pancreatic and thyroid toxicities. It states that the toxicity of the injectable agents may be higher than that of the oral...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics